USING DARK BITS TO REDUCE PHYSICAL UNCLONABLE FUNCTION (PUF) ERROR RATE WITHOUT STORING DARK BITS LOCATION

Dark-bit masking technologies for physically unclonable function (PUF) components are described. A computing system includes a processor core and a secure key manager component coupled to the processor core. The secure key manager includes the PUF component, and a dark-bit masking circuit coupled to the PUF component. The dark-bit masking circuit is to measure a PUF value of the PUF component multiple times during a dark-bit window to detect whether the PUF value of the PUF component is a dark bit. The dark bit indicates that the PUF value of the PUF component is unstable during the dark-bit window. The dark-bit masking circuit is to output the PUF value as an output PUF bit of the PUF component when the PUF value is not the dark bit and set the output PUF bit to be a specified value when the PUF value of the PUF component is the dark bit.

SECURE KEY DERIVATION AND CRYPTOGRAPHY LOGIC FOR INTEGRATED CIRCUITS

A processor of an aspect includes root key generation logic to generate a root key. The root key generation logic includes a source of static and entropic bits. The processor also includes key derivation logic coupled with the root key generation logic. The key derivation logic is to derive one or more keys from the root key. The processor also includes cryptographic primitive logic coupled with the root key generation logic. The cryptographic primitive logic is to perform cryptographic operations. The processor also includes a security boundary containing the root key generation logic, the key derivation logic, and the cryptographic primitive logic. Other processors, methods, and systems are also disclosed. 1. A processor comprising:root key generation logic to generate a root key, the root key generation logic including a source of static and entropic bits;key derivation logic coupled with the root key generation logic, the key derivation logic to derive one or more keys from the root key;cryptographic primitive logic coupled with the root key generation logic to perform cryptographic operations; anda security boundary containing the root key generation logic, the key derivation logic, and the cryptographic primitive logic.2. The processor of claim 1 , wherein the source of the static and entropic bits comprises physically unclonable function (PUF) to generate PUF bits.3. The processor of claim 2 , further comprising error correction logic and entropy extraction logic to respectively perform error correction and entropy extraction on the PUF bits claim 2 , the error correction logic and the entropy extraction logic included within the security boundary.4. The processor of claim 1 , wherein the source of the static and entropic bits comprises fuses.5. The processor of claim 1 , wherein within the security boundary scanning of logic state by external entities is disabled.6. The processor of claim 4 , further comprising test logic within the security boundary to test ...

TECHNIQUES FOR SHARED PRIVATE DATA OBJECTS IN A TRUSTED EXECUTION ENVIRONMENT

Techniques for sharing private data objects in a trusted execution environment using a distributed ledger are described. The techniques described herein may enable sharing of data objects, referred to herein as private data objects (PDOs), between individuals and organizations with access and update policies mediated by execution of code (referred to herein as a “smart contract”) carried with the PDO in a secure enclave. A distributed ledger may serve as a “public commit log” to ensure that there is a single, authoritative instance of the object and provide a means of guaranteeing atomicity of updates across interacting objects. 1. A computer-implemented method for sharing private data objects , comprising:provisioning one or more contract enclaves from a plurality of contract enclaves;preparing a contract and initial state for a private data object (PDO);receiving an encrypted and signed PDO and signature from one or more of the provisioned contract enclaves;verifying the received signature; andcommunicating the PDO and verified signature to a distributed ledger.2. The computer-implemented method of claim 1 , wherein the PDO includes one or more rights managed within a contract manager.3. The computer-implemented method of claim 2 , wherein the contract manager executes exclusively within a provisioned contract enclave.4. The computer-implemented method of claim 2 , wherein the one or more rights includes a limitation on data visibility.5. The computer-implemented method of claim 1 , wherein the distributed ledger is used as a data commit log.6. The computer-implemented method of claim 5 , wherein the distributed ledger is configured to allow claim 5 , at most claim 5 , a single authoritative instance of the PDO.7. The computer-implemented method of claim 1 , wherein interactions with the PDO can exclusively be performed within one of the provisioned contract enclaves.8. The computer-implemented method of claim 1 , wherein the PDO includes a non-deterministic smart ...

Offline Device Authentication and Anti-Counterfeiting Using Physically Unclonable Functions

The output of a physically unclonable function (PUF) may be processed to reduce its size. The post-processing result is served as a device intrinsic unclonable identifier and is signed by the device manufacturer to create a certificate stored on board the same device that includes the physically unclonable function. This scheme may not require online verification and complex error correction on PUFs in some cases. 1. A method of device authentication using a physically unclonable function comprising:generating a device certificate based on a result of the physically unclonable function; andstoring the certificate on said device.2. The method of including storing the certificate on a device having the physically unclonable function.3. The method of including reducing the signed certificate by randomly grouping the physically unclonable function into a plurality of groups.4. The method of including using majority voting to reduce each group.5. A method comprising:processing the output of a physically unclonable function to reduce a signed certificate derived from the output; andverifying the device by validating the certificate.6. The method of including signing the output with a private key to produce the certificate.7. The method of including reducing the signed certificate by randomly grouping the physically unclonable function into a plurality of groups8. The method of including using majority voting to reduce each group.9. At least one non-transitory computer readable medium storing instructions that enable a computer to:generate a device certificate based on a result of a physically unclonable function;store the certificate; andauthenticate a device using said certificate.10. The medium of further storing instructions to store the certificate on a device having the physically unclonable function.11. The medium of further storing instructions to reduce the signed certificate.12. The medium of further storing instructions to reduce the signed certificate by ...

HYDROXYALKYLAMINE- and HYDROXYCYCLOALKYLAMINE-SUBSTITUTED DIAMINE-ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS

Disclosed are compounds of Formula A, or a salt thereof: wherein R 1 , R 2 , and E are defined herein, which compounds have properties for inhibiting Na v 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A or their salts, and methods of treating pain disorders, cough, and itch using the same.

FACTOR XIa INHIBITORS

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.

Integrated circuits having accessible and inaccessible physically unclonable functions

An integrated circuit substrate of an aspect includes a plurality of exposed electrical contacts. The integrated circuit substrate also includes an inaccessible set of Physically Unclonable Function (PUF) cells to generate an inaccessible set of PUF bits that are not accessible through the exposed electrical contacts. The integrated circuit substrate also includes an accessible set of PUF cells to generate an accessible set of PUF bits that are accessible through the exposed electrical contacts. Other apparatus, methods, and systems are also disclosed.

Mutually assured data sharing between distrusting parties in a network environment

An apparatus for sharing information between entities includes a processor and a trusted execution module executing on the processor. The trusted execution module is configured to receive first confidential information from a first client device associated with a first entity, seal the first confidential information within a trusted execution environment, receive second confidential information from a second client device associated with a second entity, seal the second confidential information within the trusted execution environment, and execute code within the trusted execution environment. The code is configured to compute a confidential result based upon the first confidential information and the second confidential information.

Techniques for shared private data objects in a trusted execution environment

Techniques for sharing private data objects in a trusted execution environment using a distributed ledger are described. The techniques described herein may enable sharing of data objects, referred to herein as private data objects (PDOs), between individuals and organizations with access and update policies mediated by execution of code (referred to herein as a “smart contract”) carried with the PDO in a secure enclave. A distributed ledger may serve as a “public commit log” to ensure that there is a single, authoritative instance of the object and provide a means of guaranteeing atomicity of updates across interacting objects.

AUTO DISPLAY OF A PRODUCT LOCATION MAP ON A MOBILE DEVICE BASED ON DEVICE CONTEXT

Generally, this disclosure describes a method and system for providing product mapping on a mobile device based on device context. A method may include receiving product location data based on a context of a mobile device, wherein the product location data includes an available product location for each available product that corresponds to a desired product in a shopping list of desired products; and displaying a map of a store that sells one or more available products, wherein the store is related to the context and the map includes a product location indicator corresponding to each available product location configured to allow a user to find each available product that corresponds to a respective desired product in the store. 115-. (canceled)16. A method comprising:receiving product location data based on a context of a mobile device, wherein the product location data comprises an available product location for each available product that corresponds to a desired product in a shopping list of desired products; anddisplaying a map of a store that sells one or more available products, wherein the store is related to the context and the map comprises a product location indicator corresponding to each available product location configured to allow a user to find each available product that corresponds to a respective desired product in the store.17. The method of claim 16 , wherein the product location data is received in response to transmitting the shopping list.18. The method of claim 16 , further comprising:determining the available product location for each available product that corresponds to a desired product.19. The method of claim 16 , further comprising:determining the context of the mobile device, wherein the context comprises a location of the mobile device.20. The method of claim 16 , further comprising:determining whether at least one desired product is available.215. The method of claim claim 16 , wherein the determining whether a desired product is ...

Secure key derivation and cryptography logic for integrated circuits

A processor of an aspect includes root key generation logic to generate a root key. The root key generation logic includes a source of static and entropic bits. The processor also includes key derivation logic coupled with the root key generation logic. The key derivation logic is to derive one or more keys from the root key. The processor also includes cryptographic primitive logic coupled with the root key generation logic. The cryptographic primitive logic is to perform cryptographic operations. The processor also includes a security boundary containing the root key generation logic, the key derivation logic, and the cryptographic primitive logic. Other processors, methods, and systems are also disclosed.

Substituted benzamides and substituted pyridinecarboxamides as Btk inhibitors

The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds in the treatment of Btk mediated disorders.

SECURE KEY STORAGE USING PHYSICALLY UNCLONABLE FUNCTIONS

Some implementations disclosed herein provide techniques and arrangements for provisioning keys to integrated circuits/processors. A processor may include physically unclonable functions component, which may generate a unique hardware key based at least on at least one physical characteristic of the processor. The hardware key may be employed in encrypting a key such as a secret key. The encrypted key may be stored in a memory of the processor. The encrypted key may be validated. The integrity of the key may be protected by communicatively isolating at least one component of the processor. 1. A processor comprising:at least one interconnect;nonvolatile memory having an encrypted first key stored therein;a first logic to generate a hardware key based at least in part on at least one unique physical characteristic of the processor; anda second logic connected to the nonvolatile memory and the first logic by the at least one interconnect, the second logic to decrypt the encrypted first key with at least the hardware key to reveal the first key.2. A processor as recited in claim 1 , wherein the hardware key is unique to the processor.3. A processor as recited in claim 1 , wherein the second logic is only a decryption component.4. A processor as recited in claim 1 , wherein the nonvolatile memory includes a one-time only programmable memory.5. A processor as recited in claim 4 , wherein the nonvolatile memory includes at least one fuse.6. A processor as recited in claim 4 , wherein the nonvolatile memory includes at least one anti-fuse.7. A processor as recited in claim 1 , wherein the second logic is includes a decryption component and an encryption component.8. A processor as recited in claim 1 , further comprising:at least one contact; anda third logic to provide, at a first time, a communication path between the at least one contact and at least one of the non-volatile memory, the first logic, and the second logic, and wherein at a second time, which is later than ...

TECHNIQUES FOR SHARED PRIVATE DATA OBJECTS IN A TRUSTED EXECUTION ENVIRONMENT

Techniques for sharing private data objects in a trusted execution environment using a distributed ledger are described. The techniques described herein may enable sharing of data objects, referred to herein as private data objects (PDOs), between individuals and organizations with access and update policies mediated by execution of code (referred to herein as a “smart contract”) carried with the PDO in a secure enclave. A distributed ledger may serve as a “public commit log” to ensure that there is a single, authoritative instance of the object and provide a means of guaranteeing atomicity of updates across interacting objects. 125-. (canceled)26. A computer-implemented method for sharing private data objects , comprising:requesting a private data object (PDO) from a distributed ledger;receiving the PDO from the distributed ledger;selecting a contract enclave configured to interact with the PDO; andsubmitting the PDO and method invocation to the contract enclave.27. The computer-implemented method of claim 26 , comprising:receiving, from the contract enclave, a new iteration of the PDO, one or more signed state transitions, and one or more method parameters; andsubmitting, to the distributed ledger, the new iteration of the PDO, the one or more signed state transitions, and the one or more method parameters.28. The computer-implemented method of claim 26 , comprising provisioning the contract enclave.29. The computer-implemented method of claim 26 , wherein the PDO includes one or more rights managed within a contract manager.30. The computer-implemented method of claim 29 , wherein the contract manager executes exclusively within the contract enclave.31. The computer-implemented method of claim 29 , wherein the one or more rights includes a limitation on data visibility.32. The computer-implemented method of claim 26 , wherein the distributed ledger is used as a data commit log and is configured to allow claim 26 , at most claim 26 , a single authoritative ...

Btk inhibitors

The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or pharmaceutically acceptable salts thereof. Formula I or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds in the treatment of Btk mediated disorders.

Techniques for shared private data objects in a trusted execution environment

Techniques for sharing private data objects in a trusted execution environment using a distributed ledger are described. The techniques described herein may enable sharing of data objects, referred to herein as private data objects (PDOs), between individuals and organizations with access and update policies mediated by execution of code (referred to herein as a “smart contract”) carried with the PDO in a secure enclave. A distributed ledger may serve as a “public commit log” to ensure that there is a single, authoritative instance of the object and provide a means of guaranteeing atomicity of updates across interacting objects.

SYSTEMS, METHODS, APPARATUS AND ARTICLES OF MANUFACTURE TO PREVENT UNAUTHORIZED RELEASE OF INFORMATION ASSOCIATED WITH A FUNCTION AS A SERVICE

Systems, methods, apparatus, and articles of manufacture to prevent unauthorized release of information associated with a function as a service are disclosed. A system disclosed herein operates on in-use information. The system includes a function as a service of a service provider that operates on encrypted data. The encrypted data includes encrypted in-use data. The system also includes a trusted execution environment (TEE) to operate within a cloud-based environment of a cloud provider. The function as a service operates on the encrypted data within the TEE, and the TEE protects service provider information from access by the cloud provider. The encrypted in-use data and the service provider information form at least a portion of the in-use information. 1. A system to prevent unauthorized release of in-use information , the system comprising:a function as a service associated with a service provider, the function as a service to operate on encrypted data, the encrypted data including encrypted in-use data, the encrypted in-use data to form a first portion of the in-use information; anda trusted execution environment (TEE) to operate within a cloud-based environment of a cloud provider, the function as a service to operate on the encrypted data within the TEE, the TEE to protect service provider information from access by the cloud provider, the service provider information to form a second portion of the in-use information.2. The system of claim 1 , wherein the function as a service is implemented with a machine learning model.3. The system of claim 2 , wherein the encrypted data is homomorphically encrypted data that can be operated on by the machine learning model without undergoing decryption.4. The system of claim 2 , wherein the encrypted data is homomorphically encrypted data claim 2 , and further including a first encryptor claim 2 , the first encryptor to use a two-party encryption technique to at least one of decrypt or encrypt information claim 2 , the ...

METHODS, SYSTEMS AND APPARATUS TO FACILITATE CLIENT-BASED AUTHENTICATION

Methods, systems and apparatus are disclosed to facilitate client-based authentication. An example method includes associating an identity authority with a client platform in an isolated execution environment, associating a user identity with the identity authority, generating a first key pair associated with a first service provider, generating an attestation based on a first authorization sequence of the client platform, and signing the attestation with a portion of the key pair and sending the signed attestation to the first service provider to authorize communication between the client platform and the first service provider.

SECURE KEY STORAGE USING PHYSICALLY UNCLONABLE FUNCTIONS

Some implementations disclosed herein provide techniques and arrangements for provisioning keys to integrated circuits/processor/apparatus. In one embodiment, the apparatus includes a physically unclonable functions (PUF) circuit to generate a hardware key based on at least one manufacturing variation of the apparatus and a nonvolatile memory coupled to the PUF circuit, the nonvolatile memory to store an encrypted key, the encrypted key comprising a first key encrypted using the hardware key. The apparatus further includes a hardware cipher component coupled to the nonvolatile memory and the PUF circuit, the hardware cipher component to decrypt the encrypted key stored in the nonvolatile memory with at least the hardware key to generate a decrypted copy of the first key and fixed logic circuitry coupled to the PUF circuit and the hardware cipher component, the fixed logic circuitry to verify that the decrypted copy of the first key is valid. 1. An apparatus comprising:a physically unclonable functions (PUF) circuit to generate a hardware key based on at least one manufacturing variation of the apparatus;nonvolatile memory coupled to the PUF circuit, the nonvolatile memory to store an encrypted key, the encrypted key comprising a first key encrypted using the hardware key;a hardware cipher component coupled to the nonvolatile memory and the PUF circuit, the hardware cipher component to decrypt the encrypted key stored in the nonvolatile memory with at least the hardware key to generate a decrypted copy of the first key; andfixed logic circuitry coupled to the PUF circuit and the hardware cipher component, the fixed logic circuitry to verify that the decrypted copy of the first key is valid.2. The apparatus of claim 1 , wherein the at least one manufacturing variation results from integrated circuit fabrication of the apparatus.3. The apparatus of claim 1 , wherein the nonvolatile memory includes at least one anti-fuse.4. The apparatus of claim 1 , wherein the ...

Piperizinylpiperidine derivatives as chemokine receptor antagonists

The present invention relates to compounds of Formula (I): wherein variable substituents are defined herein, that modulate the activity of or bind to chemokine receptors such as CCR5. In some embodiments, the compounds of the invention are selective for CCR5. The compounds can be used, for example, to treat diseases associated with chemokine receptor expression or activity such as inflammatory diseases, immune diseases and viral infections.

SECURED CREDENTIAL AGGREGATOR

An apparatus for aggregating secured credentials is described herein. The apparatus includes a processor and a memory. The memory includes code causing the processor to provision a plurality of secured credentials on the apparatus. The code causes the processor to isolate the secured credentials from each other in the memory. The code also causes the processor to emulate a selected secured credential from the secured credentials for a transaction. 1. An apparatus for aggregating secured credentials , the apparatus comprising:a processor; provision a plurality of secured credentials on the apparatus;', 'isolate the secured credentials from each other in the memory; and', 'emulate a selected secured credential from the secured credentials for a transaction., 'a memory comprising code causing the processor to2. The apparatus of claim 1 , comprising:a display; anda user interface that enables selection of the selected secured credential.3. The apparatus of claim 2 , wherein the user interface comprises a button claim 2 , wherein pressing the button when the apparatus is asleep wakes the apparatus.4. The apparatus of claim 3 , wherein subsequent button presses display a representation of each of the secured credentials.5. The apparatus of claim 1 , comprising a biometric sensor that prevents an unauthorized user from using the apparatus.6. The apparatus of claim 1 , comprising a credential interface claim 1 , wherein the credential interface is used for provisioning the secured credentials claim 1 , and emulating the selected secured credential.7. The apparatus of claim 6 , wherein the credential interface comprises smartcard contacts.8. The apparatus of claim 6 , wherein the credential interface comprises an embedded antenna.9. The apparatus of claim 1 , comprising a power source.10. The apparatus of claim 9 , the power source comprising a rechargeable battery.11. The apparatus of claim 10 , comprising a DC switchover mechanism that enables the apparatus to be powered ...

System and method for verification of off-chip processor code

An electronic system and corresponding method for verifying the integrity of code that is stored off-chip. The electronic system comprises a memory element to store Processor Abstraction Layer (PAL) code and a processor coupled to the memory element. The processor verifies the integrity of the PAL code prior to execution of the PAL code.

Using dark bits to reduce physical unclonable function (PUF) error rate without storing dark bits location

Dark-bit masking technologies for physically unclonable function (PUF) components are described. A computing system includes a processor core and a secure key manager component coupled to the processor core. The secure key manager includes the PUF component, and a dark-bit masking circuit coupled to the PUF component. The dark-bit masking circuit is to measure a PUF value of the PUF component multiple times during a dark-bit window to detect whether the PUF value of the PUF component is a dark bit. The dark bit indicates that the PUF value of the PUF component is unstable during the dark-bit window. The dark-bit masking circuit is to output the PUF value as an output PUF bit of the PUF component when the PUF value is not the dark bit and set the output PUF bit to be a specified value when the PUF value of the PUF component is the dark bit.

Techniques for shared private data objects in a trusted execution environment

Techniques for sharing private data objects in a trusted execution environment using a distributed ledger are described. The techniques described herein may enable sharing of data objects, referred to herein as private data objects (PDOs), between individuals and organizations with access and update policies mediated by execution of code (referred to herein as a “smart contract”) carried with the PDO in a secure enclave. A distributed ledger may serve as a “public commit log” to ensure that there is a single, authoritative instance of the object and provide a means of guaranteeing atomicity of updates across interacting objects.

SECURE KEY STORAGE USING PHYSICALLY UNCLONABLE FUNCTIONS

Some implementations disclosed herein provide techniques and arrangements for provisioning keys to integrated circuits/processor. In one embodiments, a key provisioner/tester apparatus may include a memory device to receive a unique hardware key generated by a first logic of a processor. The key provisioner/tester apparatus may further include a cipher device to permanently store an encrypted first key in nonvolatile memory of the processor, detect whether the stored encrypted first key is valid, and to isolate at least one of the first logic and the nonvolatile memory of the processor from all sources that are exterior to the processor in response to detecting that the stored encrypted first key is valid. 1. A method of provisioning a key to a processor , comprising:receiving a unique hardware key generated by a first logic of the processor;permanently storing an encrypted first key in nonvolatile memory of the processor;detecting whether the stored encrypted first key is valid; andisolating at least one of the first logic and the nonvolatile memory of the processor from all sources that are exterior to the processor in response to detecting that the stored encrypted first key is valid.2. A method as recited in claim 1 , wherein the permanently storing an encrypted first key in nonvolatile memory of the processor comprises:encrypting the first key with the hardware key at a cipher device that is external to the processor; andwriting, by a device that is external to the processor, the encrypted first key into the nonvolatile memory.3. A method as recited in claim 2 , wherein the detecting whether the stored encrypted first key is valid comprises:reading, by a device that is external to the processor, the encrypted first key from the nonvolatile memory;decrypting the read encrypted first key with the hardware key at the cipher device that is external to the processor to reveal a purported first key; andemploying at least a portion of the purported first key in the ...

Secure key storage using physically unclonable functions

Some implementations disclosed herein provide techniques and arrangements for provisioning keys to integrated circuits/processors. A processor may include physically unclonable functions component, which may generate a unique hardware key based at least on at least one physical characteristic of the processor. The hardware key may be employed in encrypting a key such as a secret key. The encrypted key may be stored in a memory of the processor. The encrypted key may be validated. The integrity of the key may be protected by communicatively isolating at least one component of the processor.

System and method for authentication of off-chip processor firmware code

An electronic system and corresponding method for authenticating firmware stored in a memory element external to a processor. In one embodiment, an electronic system comprises a processor and a memory element. The memory element is used to contain firmware and a digital signature of the firmware signed by a signatory. Coupled to the memory element, the processor authenticates the firmware during a predetermined condition, which occurs prior to execution of the firmware, through use of a pre-stored public key of the signatory and a pre-stored digital signature function.

INTEGRATED CIRCUITS HAVING ACCESSIBLE AND INACCESSIBLE PHYSICALLY UNCLONABLE FUNCTIONS

An integrated circuit substrate of an aspect includes a plurality of exposed electrical contacts. The integrated circuit substrate also includes an inaccessible set of Physically Unclonable Function (PUF) cells to generate an inaccessible set of PUF bits that are not accessible through the exposed electrical contacts. The integrated circuit substrate also includes an accessible set of PUF cells to generate an accessible set of PUF bits that are accessible through the exposed electrical contacts. Other apparatus, methods, and systems are also disclosed. 1. An integrated circuit substrate comprising:a plurality of exposed electrical contacts;an inaccessible set of Physically Unclonable Function (PUF) cells to generate an inaccessible set of PUF bits that are not accessible through the exposed electrical contacts; andan accessible set of PUF cells to generate an accessible set of PUF bits that are accessible through the exposed electrical contacts.2. The integrated circuit substrate of claim 1 , further comprising logic to allow the accessible set of PUF bits to be accessible through the exposed electrical contacts claim 1 , and wherein there is no logic to allow the inaccessible set of PUF bits to be accessible through the exposed electrical contacts.3. The integrated circuit substrate of claim 1 , wherein the inaccessible set of PUF bits are to be provided to security logic for use in security and the accessible set of PUF bits are not to be provided to the security logic for use in security.4. The integrated circuit substrate of claim 1 , further comprising:security logic;logic to provide the inaccessible set of PUF bits to the security logic, andwherein there is no logic to provide the accessible set of PUF bits to the security logic.5. The integrated circuit substrate of claim 1 , wherein the accessible set of PUF cells are within a region more enabled for debug than a region having the inaccessible set of PUF cells.6. The integrated circuit substrate of claim 1 , ...

SMART DEVICE ASSISTED COMMERCE

Systems, devices, and methods used to provide real-time product information for retail products and services are generally disclosed herein. One example embodiment includes a referral application operating on a smartphone, configured to correlate data from multiple sources and provide context-aware recommendations and information relevant to a product or service being evaluated by a consumer in the physical shopping environment (such as a retail store). For example, the data may be obtained from a retailer's product information database, a retailer's competitor information database, an advertiser information database, an Internet-hosted service, a social network, or similar internal or external information sources. The real-time product information may be correlated, aggregated, and displayed to the user to either facilitate the retail purchase in the store, or encourage another online or retail purchase. Techniques for providing location-based advertisements and tailored product offerings based on the user's shopping activity are also described herein. 1. A mobile wireless device , comprising:at least one processor; and identify a product using a product identifier, the product having a physical display in a commerce environment;', 'retrieve product information using the product identifier from at least one product information data source;', 'determine real-time product information by correlating the product information to the physical display of the product and user activity in the commerce environment; and', 'display the real-time product information in a user interface provided by the mobile wireless device., 'at least one memory device providing a plurality of instructions that, when executed by the processor, cause the processor to perform operations that2. The mobile wireless device of claim 1 , further comprising:a camera to capture an image of the physical display;wherein the instructions to retrieve product information include instructions to obtain the ...

Secure key storage

Some implementations disclosed herein provide techniques and arrangements for provisioning keys to integrated circuits/processor. In one embodiments, a key provisioner/tester apparatus may include a memory device to receive a unique hardware key generated by a first logic of a processor. The key provisioner/tester apparatus may further include a cipher device to permanently store an encrypted first key in nonvolatile memory of the processor, detect whether the stored encrypted first key is valid, and to isolate at least one of the first logic and the nonvolatile memory of the processor from all sources that are exterior to the processor in response to detecting that the stored encrypted first key is valid.

AUTOMATED SECURE CHECK-OUT AND DROP-OFF RETURN OF PRODUCTS USING MOBILE DEVICE

Generally, this disclosure describes a method and system for automated check-out and drop-off return of products using a mobile device. A method may include purchasing at least one product of a plurality of products wherein each product is located at a respective associated product location in a store that sells the plurality of products and a point of sale of each purchased product corresponds to the respective associated product location. 114-. (canceled)15. A method comprising:purchasing at least one product of a plurality of products wherein each product is located at a respective associated product location in a store that sells the plurality of products and a point of sale of each purchased product corresponds to the respective associated product location.16. The method of claim 15 , further comprising:identifying each product based on a product identifier tag associated with each product wherein the product identifier tag is the same for a plurality of the same product.17. The method of claim 15 , further comprising:identifying one product based on an individual product tag associated with the one product wherein the individual tag is configured uniquely identify the one product and to indicate a purchase state of the one product.18. The method of claim 15 , further comprising:receiving an electronic receipt in response to each product being purchased.19. The method of claim 15 , further comprising:updating a purchase state associated with each product in response to the product being purchased.20. The method of claim 15 , further comprising:releasing a security device attached to one product in response to the one product being purchased.21. The method of claim 15 , further comprising:receiving an electronic credit receipt in response to one purchased product being returned to a product return facility configured to receive returned products if the purchased product is in a returnable condition, wherein the returning is performed without interaction with a ...

Indole derivatives useful as anti-diabetic agents

Novel compounds of the structural formula (I) are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.

Piperazine-substituted [1,2,4]triazolo[1,5-C]quinazolin-5-amine compounds with A2A antagonist properties

Disclosed are compounds of Formula A: (structurally represented) where “RG1”, “RG2a”, “RG4”, “RG5”, “MG1”, “n” and “m” are defined herein which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2a receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.

Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents

Novel compounds of structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.

Automated secure check-out and drop-off return of products using mobile device

Generally, this disclosure describes a method and system for automated check-out and drop-off return of products using a mobile device. A method may include purchasing at least one product of a plurality of products wherein each product is located at a respective associated product location in a store that sells the plurality of products and a point of sale of each purchased product corresponds to the respective associated product location.

TECHNIQUES FOR SHARED PRIVATE DATA OBJECTS IN A TRUSTED EXECUTION ENVIRONMENT

Techniques for sharing private data objects in a trusted execution environment using a distributed ledger are described. The techniques described herein may enable sharing of data objects, referred to herein as private data objects (PDOs), between individuals and organizations with access and update policies mediated by execution of code (referred to herein as a “smart contract”) carried with the PDO in a secure enclave. A distributed ledger may serve as a “public commit log” to ensure that there is a single, authoritative instance of the object and provide a means of guaranteeing atomicity of updates across interacting objects.

TECHNIQUES FOR SHARED PRIVATE DATA OBJECTS IN A TRUSTED EXECUTION ENVIRONMENT

Techniques for sharing private data objects in a trusted execution environment using a distributed ledger are described. The techniques described herein may enable sharing of data objects, referred to herein as private data objects (PDOs), between individuals and organizations with access and update policies mediated by execution of code (referred to herein as a “smart contract”) carried with the PDO in a secure enclave. A distributed ledger may serve as a “public commit log” to ensure that there is a single, authoritative instance of the object and provide a means of guaranteeing atomicity of updates across interacting objects. 1. A computer-implemented method , comprising:registering a contract identifier with a distributed ledger selecting one or more of a plurality of contract enclaves;requesting a provisioning secret for the one or more of the plurality of contract enclaves; andsending an information element comprising indication of private data to at least one of the one or more of the plurality of contract enclaves.2. The computer-implemented method of claim 1 , wherein claim 1 , the at least one of the one or more of the plurality of contract enclaves create a private data object (PDO) responsive to receiving the information element and send the PDO to the distributed ledger.3. The computer-implemented method of claim 1 , wherein the provisioning secret comprising at least an encryption public key for the one or more of the plurality of contract enclaves.4. The computer-implemented method of claim 1 , comprising selecting the one or more of the plurality of contract enclaves based on at least one of the following: processor claim 1 , memory claim 1 , latency claim 1 , security claim 1 , or software.5. The computer-implemented method of claim 1 , comprising registering a contract owner public key with the distributed ledger.6. The computer-implemented method of claim 1 , comprising receiving from a provisioning service a keyshare encrypted with an encryption ...

PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS

The present invention relates to compounds of Formula I: 118-. (canceled)20. The method of wherein said chemokine receptor is CCR5.21. The method of wherein said modulating corresponds to inhibiting.22. The method of wherein said compound is a selective inhibitor of CCR5.23. The method of wherein said compound is a selective binder of CCR5.25. The method of wherein said chemokine receptor is CCR5.26. The method of wherein said compound is a selective inhibitor or binder of CCR5.28. The method of wherein said disease or condition is an inflammatory disease.29. The method of wherein said disease or condition is an immune disorder.30. The method of wherein said disease or condition is a viral infection.31. The method of wherein said viral infection is HIV infection.33. The method of further comprising simultaneously or sequentially administering at least one anti-viral agent.35. The method of wherein the compound is 5-[(4-{(3S)-4-[(1R claim 34 ,2R)-2-Ethoxy-5-(trifluoromethyl)-2 claim 34 ,3-dihydro-1H-inden-1-yl]-3-methylpiperazin-1-yl}-4-methylpiperidin-1-yl)carbonyl]-4 claim 34 ,6-dimethylpyrimidine claim 34 , or a pharmaceutically acceptable salt thereof.36. The method of wherein the compound is 5-[(4-{(3S)-4-[(1R claim 34 ,2R)-2-Ethoxy-5-(trifluoromethyl)-2 claim 34 ,3-dihydro-1H-inden-1-yl]-3-methylpiperazin-1-yl}-4-methylpiperidin-1-yl)carbonyl]-4 claim 34 ,6-dimethylpyrimidine dihydrochloride.37. The method of wherein the compound is 5-[(4-{(3S)-4-[(1R claim 34 ,2R)-2-Ethoxy-5-(1 claim 34 ,3-thiazol-2-yl)-2 claim 34 ,3-dihydro-1H-inden-1-yl]-3-methylpiperazin-1-yl}-4-methylpiperidin-1-yl)carbonyl]-4 claim 34 ,6-dimethylpyrimidine claim 34 , or a pharmaceutically acceptable salt thereof.38. The method of wherein the compound is 5-[(4-{-4-[2-ethoxy-5-(trifluoromethyl)-2 claim 34 ,3-dihydro-1H-inden-1-yl]-3-methylpiperazin-1-yl}-4-methylpiperidin-1-yl)carbonyl]-4 claim 34 ,6-dimethylpyrimidine claim 34 , or a pharmaceutically acceptable salt thereof.39. The method ...

NOVEL CYCLIC AZABENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS

Novel compounds of structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension. 2. The compound according to wherein:{'sup': '3', 'T is selected from the group consisting of: CR, N and N-oxide;'}{'sup': '1', 'U is selected from the group consisting of: CR, N and N-oxide;'}{'sup': '2', 'V is selected from the group consisting of: CR, N and N-oxide;'}{'sup': '4', 'W is selected from the group consisting of: CR, N and N-oxide,'}provided that at least one of T, U, V and W is N or N-oxide; [{'sub': '2', '(1) —CH—,'}, '(2) —CHF—,', {'sub': '2', '(3) —CF—,'}, '(4) —S—,', '(5) —O—,', {'sub': '2', '(6) —O—CH—,'}, '(7) —NH—,', '(8) —C(O)—,', '(9) —NHC(O)—,', '(10) —C(O)NH—,', {'sub': '2', '(11) —NHSO—,'}, {'sub': '2', '(12) —SONH—, and'}, {'sub': '2', '(13) —CO—,'}], 'X is absent or selected from{'sub': 2', '2', '1-6', '2', '2', '1-6', '1-6', '2', '1-6', '2', '2', '1-6', '1-6', '2, 'wherein each CHis unsubstituted or substituted with 1 or 2 substituents selected from: hydroxy, halogen, NH, Calkyl, COH, COCalkyl, COCalkyl, phenyl and —CH-phenyl, and wherein each NH is unsubstituted or substituted with 1 substituent selected from: Calkyl, COH, COCalkyl, COCalkyl, phenyl and —CH-phenyl;'} [{'sub': '3-10', '(1) Ccycloalkyl,'}, {'sub': '3-10', '(2) Ccycloalkenyl,'}, {'sub': '2-10', '(3) Ccycloheteroalkyl,'}, {'sub': '2-10', '(4) Ccycloheteroalkenyl,'}, '(5) aryl, and', '(6) heteroaryl,, 'Y is selected from{'sup': 'b', 'wherein cycloalkyl, cycloalkenyl, cycloheteroalkyl, cycloheteroalkenyl, aryl and heteroaryl are unsubstituted or substituted with 1, 2, 3 or 4 substituents selected from R;'} (1) oxo,', '(2) —CN,', {'sub': '3', '(3) —CF,'}, {'sub': '1-6', '(4) —Calkyl,'}, {'sub': 2', 't, '(5) —(CH)- ...

Substituted cycloproply compounds, compositions containing such compounds and methods of treatment

Substituted cyclopropyl compounds of the formula I: and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR-119. Pharmaceutical compositions and methods of treatment are also included

NOVEL INDOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS

Novel compounds of the structural formula (I) are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension. 3. The compound according to claim 1 , wherein{'sup': '3', 'T is selected from —CR— and N;'}{'sup': '1', 'U is —CR—;'}{'sup': '2', 'V is —CR—; and'}{'sup': '4', 'W is selected from —CR— and N,'}{'sup': 1', '2, 'sub': 3', '1-6', '2-6', '2-6', '3', '1-6', '2-6', '2-6, 'provided that one of T and W is N, and further provided that if W is N, then Ris selected from hydrogen, halogen, —CN, —CF, —Calkyl, —Calkenyl and —Calkynyl, and if T is N then Ris selected from hydrogen, halogen, —CN, —CF, —Calkyl, —Calkenyl and —Calkynyl;'}or a pharmaceutically acceptable salt thereof.4. The compound according to claim 1 , wherein T is —CR— or N; U is —CR—; V is —CR—; and W is —CR—; or a pharmaceutically acceptable salt thereof.5. The compound according to claim 1 , wherein X is absent or selected from:{'sub': '2', '(1) —CH—,'}(2) —S—,(3) —S(O)—,{'sub': '2', '(4) —S(O)—,'}(5) —O—,{'sub': '2', '(6) —O—CH—,'}{'sub': '2', '(7) —CH—O—,'}{'sub': '2', '(8) —CH—S—,'}(9) —NH—,(10) —C(O)—, and(11) —C(O)NH—,{'sub': 2', '2', '1-6', '2', '2', '1-6', '1-6', '1-6', '2', '2', '1-6', '1-6, 'wherein each CHis unsubstituted or substituted with 1 or 2 substituents selected from: hydroxy, halogen, NH, Calkyl, COH, COCalkyl, and COCalkyl, and wherein each NH is unsubstituted or substituted with 1 substituent selected from: Calkyl, COH, COCalkyl, and COCalkyl;'}or a pharmaceutically acceptable salt thereof.6. The compound according to claim 4 , wherein X is —CH—; or a pharmaceutically acceptable salt thereof.8. The compound according to claim 6 , wherein Y is selected from:{'sub': '1-6', '(1) Calkyl,'}{'sub': '3-10', '(2) Ccycloalkyl, ...

BTK INHIBITORS

Provided are 6-5 membered fused pyridine ring compounds according to Formula (I) or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and their use in therapy. In particular, provided is the use of 6-5 membered fused pyridine ring compounds in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders. 1. (canceled)2. (canceled)3. The compound of claim 38 , wherein ring K is defined as: Bis C(R) claim 38 , Bis C(R) claim 38 , Bis C(R) claim 38 , and Bis C(R); and R claim 38 , R claim 38 , Rand Reach are H or halogen.4. (canceled)5. The compound of claim 38 , wherein ring L is selected from the group consisting of pyridyl claim 38 , pyrimidyl claim 38 , and thiazolyl.6. The compound of claim 38 , wherein Ris selected from the group consisting of hydrogen claim 38 , fluorine claim 38 , chlorine claim 38 , CN claim 38 , cyclopropyl claim 38 , (1-3C)alkyl and (1-2C) alkoxy; the (1-3C)alkyl group of which is optionally substituted with one or more halogen.7. The compound of claim 6 , wherein Ris selected from the group consisting of hydrogen claim 6 , fluorine claim 6 , methyl claim 6 , ethyl claim 6 , propyl claim 6 , cyclopropyl claim 6 , methoxy and trifluoromethyl.8. The compound of claim 38 , wherein Ris selected from the group consisting of: RC(O) claim 38 , RNHC(O) claim 38 , RC(O)NH claim 38 , RSO claim 38 , (3-7C)cycloalkyl(1-4C)alkyl claim 38 , (6-10C)aryl(1-4C)alkyl claim 38 , (1-6C)alkyl claim 38 , (1-5C)heteroaryl(1-4C)alkyl claim 38 , halo(1-6C)alkyl claim 38 , hydroxyl(1-6Calkyl claim 38 , (1-4C)alkoxy(1-6C)alkyl claim 38 , (1-4C)alkoxy(1-6C)alkyl and (1-6C)alkoxyl.9. The compound of claim 8 , wherein Ris selected from the group consisting of: RC(O) claim 8 , RNHC(O) claim 8 , RC(O)NH claim 8 , (6-10C)aryl(1-4C)alkyl claim 8 , (1-5C)heteroaryl(1-4C)alkyl claim 8 , halo(1-6C)alkyl claim 8 , hydroxyl(1-6Calkyl claim 8 , (1-4C)alkoxy(1-6C)alkyl claim 8 , (1-4C)alkoxy(1-6C)alkyl and (1-6C)alkoxyl.10. The ...

MUTUALLY ASSURED DATA SHARING BETWEEN DISTRUSTING PARTIES IN A NETWORK ENVIRONMENT

An apparatus for sharing information between entities includes a processor and a trusted execution module executing on the processor. The trusted execution module is configured to receive first confidential information from a first client device associated with a first entity, seal the first confidential information within a trusted execution environment, receive second confidential information from a second client device associated with a second entity, seal the second confidential information within the trusted execution environment, and execute code within the trusted execution environment. The code is configured to compute a confidential result based upon the first confidential information and the second confidential information. 1. An apparatus for sharing information between entities , comprising:a processor; and receive first confidential information from a first client device associated with a first entity;', 'seal the first confidential information within a trusted execution environment;', 'receive second confidential information from a second client device associated with a second entity;', 'seal the second confidential information within the trusted execution environment; and', 'execute code within the trusted execution environment, the code configured to compute a confidential result based upon the first confidential information and the second confidential information., 'a trusted execution module executing on the processor, the trusted execution module configured to2. The apparatus of claim 1 , the trusted execution module being further configured to:receive the code from at least one of the first client device and the second client device; andseal the code within the trusted execution environment.3. The apparatus of claim 1 , the trusted execution module being further configured to:determine an identity of the code;send the identity to the first client device; andreceive an indication from the first device that the identity has been verified by the ...

PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS

The present invention relates to compounds of Formula I: 2. The compound of wherein Ris a 5- claim 1 , 6- claim 1 , 9- or 10-membered heteroaryl group containing at least one ring-forming N atom claim 1 , wherein said 5- claim 1 , 6- claim 1 , 9- or 10-membered heteroaryl group is optionally substituted by 1 claim 1 , 2 claim 1 , 3 or 4 Rgroups.6. The compound of wherein Ris H claim 1 , C-Calkyl claim 1 , C-Chaloalkyl claim 1 , OR claim 1 , SRor NRR.7. The compound of wherein Ris H or OR.8. The compound of wherein Ris F claim 1 , Br claim 1 , CF claim 1 , or 6- or 5-membered heteroaryl.9. The compound of wherein Ris C-Calkyl.10. The compound of wherein Ris methyl.11. The compound of wherein Ris C-Calkyl.12. The compound of wherein Ris methyl.16. The compound of characterized as a selective binder or inhibitor of CCR5.17. The compound of selected from:5-({4-[(3S)-4-(5-bromo-2,3-dihydro-1H-inden-1-yl)-3-methylpiperazin-1-yl]-4-methylpiperidin-1-yl}carbonyl)-4,6-dimethylpyrimidine;5-({4-[(3S)-4-(5-fluoro-2,3-dihydro-1H-inden-1-yl)-3-methylpiperazin-1-yl]-4-methylpiperidin-1-yl}carbonyl)-4,6-dimethylpyrimidine;5-({4-[(3S)-4-(6-bromo-2,3-dihydro-1H-inden-1-yl)-3-methylpiperazin-1-yl]-4-methylpiperidin-1-yl}carbonyl)-4,6-dimethylpyrimidine;5-({4-[(3S)-4-(6-fluoro-2,3-dihydro-1H-inden-1-yl)-3-methylpiperazin-1-yl]-4-methylpiperidin-1-yl}carbonyl)-4,6-dimethylpyrimidine;5-({4-[(3S)-4-(6-bromo-1,2,3,4-tetrahydronaphthalen-1-yl)-3-methylpiperazin-1-yl]-4-methylpiperidin-1-yl}carbonyl)-4,6-dimethylpyrimidine;5-({4-[(3S)-4-(7-bromo-1,2,3,4-tetrahydronaphthalen-1-yl)-3-methylpiperazin-1-yl]-4-methylpiperidin-1-yl}carbonyl)-4,6-dimethylpyrimidine;4,6-dimethyl-5-[(4-methyl-4-{(3S)-3-methyl-4-[6-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl]piperazin-1-yl}piperidin-1-yl)carbonyl]pyrimidine;4,6-dimethyl-5-[(4-methyl-4-{(3S)-3-methyl-4-[5-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl]piperazin-1-yl}piperidin-1-yl)carbonyl]pyrimidine;1-((2S)-4-{1-[(4,6-dimethylpyrimidin-5-yl)carbonyl]-4- ...

System and Method for Preparing Hydrocarbon Blend from Multiple Component Streams

A computer implemented blend control system and method for preparation of a hydrocarbon blend from a plurality of components drawn from respective component tanks have been disclosed. The system, in accordance with the present disclosure includes at least one sensing and analyzing means adapted to sense and analyze a first attribute of at least one of the components for obtaining first attribute data. The system further includes, at least one optimizing means having a data storage means for storing attribute based model data. The optimizing means receives the first attribute data and transmits the received first attribute data to a comparator means which computes an optimized proportion data between each of the component streams to enable selective drawing of each of the component streams in accordance with the optimized proportion data for preparing the hydrocarbon blend. 1. A computer implemented blend control system for preparation of a hydrocarbon blend from a plurality of components drawn from respective component tanks , said system comprising:a) at least one sensing and analyzing means adapted to sense and analyze a first attribute of at least one of the components for obtaining first attribute data; and i) a data storage means for storing attribute based model data;', 'ii) a receiving means for receiving the first attribute data; and', 'iii) a comparator means adapted to compare the first attribute data with the attribute based model data, the comparator means further adapted to compute an optimized proportion data between each of the component streams to enable selective drawing of each of the component streams in accordance with the optimized proportion data for preparing the hydrocarbon blend., 'b) at least one optimizing means having2. The blend control system as claimed in further comprising a flow regulating means operatively connected to the at least one optimizing means and individual component tanks claim 1 , said flow regulating means adapted to ...

Computer Implemented Blend Control System and Method for Preparation of a Hydrocarbon Blend

A computer implemented blend control system and method for preparation of a hydrocarbon blend from a plurality of component streams have been disclosed. The system includes a product tank for receiving a mixture comprising the plurality of component streams. The system further includes a sensing and analyzing means adapted to sense and analyze a first attribute of the received mixture for obtaining a first attribute data. The system further includes an optimizing means which stores the attribute based model data, receives the first attribute data and compares the received first attribute data with the attribute based model data to compute an optimized proportion data, based on which the component streams are selectively drawn into the product tank for preparing the hydrocarbon blend. 1. A computer implemented blend control system for preparation of a hydrocarbon blend from a plurality of component streams , said system comprising:a) a product tank for receiving a mixture comprising the plurality of component streams;b) at least one sensing and analyzing means adapted to sense and analyze a first attribute of the received mixture for obtaining a first attribute data; and i) data storage means for storing attribute based model data,', 'ii) receiving means for receiving said first attribute data, and', 'iii) comparator means adapted to compare the first attribute data with the model data, the comparator means further adapted to compute an optimized proportion data between each of streams in the plurality of component streams to enable selective drawing of the component streams into the product tank for preparing the hydrocarbon blend., 'c) at least one optimizing means having,'}2. The blend control system as claimed in claim 1 , further comprising a flow regulating means cooperating with the at least one optimizing means and to the product tank claim 1 , the flow regulating means adapted to control the flow of the component streams into the product tank based on the ...

BTK INHIBITORS

The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I 3. The compound of claim 1 , wherein ring K is defined as:{'sub': 1', '2', '3', '4, 'sup': 7', '8', '9', '10, 'Bis C(R), Bis C(R), Bis C(R), and Bis C(R); or'}{'sub': 1', '2', '3', '4, 'sup': 9', '10, 'Bis N, Bis N, Bis C(R), and Bis C(R); or'}{'sub': 1', '2', '3', '4, 'sup': 8', '10, 'Bis N, Bis C(R), Bis N, and Bis C(R); or'}{'sub': 1', '2', '3', '4, 'sup': 8', '9, 'Bis N, Bis C(R), Bis C(R), and Bis N; or'}{'sub': 1', '2', '3', '4, 'sup': 7', '8, 'Bis C(R), Bis C(R), Bis N, and Bis N; or'}{'sub': 1', '2', '3', '4, 'sup': 7', '9, 'Bis C(R), Bis N, Bis C(R), and Bis N.'}4. The compound of claim 3 , wherein ring K is defined as: Bis C(R) claim 3 , Bis C(R) claim 3 , Bis C(R) claim 3 , and Bis C(R) claim 3 , and wherein R claim 3 , R claim 3 , Rand Reach are H claim 3 , halogen claim 3 , (1-3C)alkyl claim 3 , (1-3C)alkoxy or halo(1-3C)alkyl; any alkoxy may optionally be substituted with one claim 3 , two or three halogen.5. The compound of claim 1 , wherein ring L is selected from the group consisting of phenyl claim 1 , pyridyl claim 1 , pyrimidyl claim 1 , pyridazyl claim 1 , triazinyl claim 1 , thiazolyl claim 1 , oxazolyl claim 1 , isoxazolyl claim 1 , pyrazolyl claim 1 , imidazolyl claim 1 , thiadiazolyl claim 1 , and isothiazolyl.7. The compound of claim 5 , wherein ring L is pyridyl.8. The compound of claim 1 , wherein Ris selected from the group consisting of hydrogen claim 1 , fluorine claim 1 , chlorine claim 1 , CN claim 1 , cyclopropyl claim 1 , cyclobutyl claim 1 , oxetanyl claim 1 , (1-3C)alkyl claim 1 , (1-5C) alkoxy claim 1 , and (1-5C)cycloalkoxy; the alkyl claim 1 , alkoxy claim 1 , cycloalkyl and cycloalkoxy of which are optionally substituted with one or more halogen.9. The compound of claim 8 , wherein Ris selected from the group consisting of hydrogen claim 8 , fluorine claim 8 , methyl claim 8 , ethyl claim 8 , propyl claim 8 , cyclopropyl ...

INDAZOLE AND AZAINDAZOLE BTK INHIBITORS

The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, wherein X, X, R, R, Rand Rare as herein described. The present invention also provides pharmaceutical compositions comprising these compounds and methods for their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders. 2. The compound of or a pharmaceutically acceptable salt thereof claim 1 , wherein Xis C(R).3. The compound of or a pharmaceutically acceptable salt thereof claim 1 , wherein Xand Xare both C(H).4. The compound of or a pharmaceutically acceptable salt thereof claim 1 , wherein Ris H.5. The compound of or a pharmaceutically acceptable salt thereof claim 1 , wherein Ris{'sup': 7a', '7b', '7a', '7b', '7a', '7b, '(a.) a group of the formula —C(O)N(R)(R), wherein Rand Rare independently H or methyl; or alternatively, Rand Rtogether with the N to which they are attached form a morpholinyl ring;'}{'sup': 'c', 'claim-text': [{'sub': '1-4', '(i.) Calkyl,'}, {'sup': '7d', 'sub': 2', '2, 'claim-text': {'sup': '7d', 'wherein Ris H or methyl;'}, '(ii.) a group of the formula —C(R)COH,'}, {'sub': 2', '2', '3, '(iii.) —CHCHOCH; or'}, '(iv.) tetrahydropyranyl;, '(b.) Cy, wherein Cy is phenyl, pyrazolyl, or pyridinyl; wherein Cy is unsubstituted or substituted by 1 to 2 Rsubstituents selected from(c.) —C(O)OH;(d.) H;(e.) methyl; or(f) trifluoromethyl.6. The compound of or a pharmaceutically acceptable salt thereof claim 1 , wherein Ris hydroxymethyl or methyl.10. A pharmaceutical composition comprising the compound of or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.11. The pharmaceutical composition of claim 10 , which further comprises at least one additional therapeutically active agent.12. The compound of or a pharmaceutically acceptable salt thereof for use in therapy.13. ...

BTK INHIBITORS

Provided are 6-5 membered fused pyridine ring compounds according to Formula (I) or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and their use in therapy. In particular, provided is the use of membered fused pyridine ring compounds in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders. 2. The compound of claim 1 , wherein ring K is defined as:{'sub': 1', '2', '3', '4, 'sup': 7', '8', '9', '10, 'Bis C(R), Bis C(R), Bis C(R), and Bis C(R); or'}{'sub': 1', '2', '3', '4, 'sup': 9', '10, 'Bis N, Bis N, Bis C(R), and Bis C(R); or'}{'sub': 1', '2', '3', '4, 'sup': 8', '10, 'Bis N, Bis C(R), Bis N, and Bis C(R); or'}{'sub': 1', '2', '3', '4, 'sup': 8', '9, 'Bis N, Bis C(R), Bis C(R), and Bis N; or'}{'sub': 1', '2', '3', '4, 'sup': 7', '8, 'Bis C(R), Bis C(R), Bis N, and Bis N; or'}{'sub': 1', '2', '3', '4, 'sup': 7', '9, 'Bis C(R), Bis N, Bis C(R), and Bis N.'}3. The compound of claim 2 , wherein ring K is defined as: Bis C(R) claim 2 , Bis C(R) claim 2 , Bis C(R) claim 2 , and Bis C(R); and R claim 2 , R claim 2 , Rand Reach are H or halogen.4. The compound of claim 1 , wherein ring L is selected from the group consisting of pyridyl claim 1 , pyrimidyl claim 1 , pyridazyl claim 1 , triazinyl claim 1 , thiazolyl claim 1 , oxazolyl claim 1 , isoxazolyl claim 1 , pyrazolyl claim 1 , thiadiazolyl claim 1 , and isothiazolyl.5. The compound of claim 4 , wherein ring L is selected from the group consisting of pyridyl claim 4 , pyrimidyl claim 4 , and thiazolyl.6. The compound of claim 1 , wherein Ris selected from the group consisting of hydrogen claim 1 , fluorine claim 1 , chlorine claim 1 , CN claim 1 , cyclopropyl claim 1 , (1-3C)alkyl and (1-2C) alkoxy; the (1-3C)alkyl group of which is optionally substituted with one or more halogen.7. The compound of claim 6 , wherein Ris selected from the group consisting of hydrogen claim 6 , fluorine claim 6 , methyl claim 6 , ethyl claim 6 , propyl claim 6 , ...

Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels

Disclosed are compounds of Formula A, or a salt thereof: Formula (A), wherein: Het, Q and R 1A to R 4A are defined herein, which compounds have properties for blocking Na v 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A or their salts, and methods of treating cough, itch, acute pain and neuropathic pain disorders using the same.

PIPERAZINE-SUBSTITUTED [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES

Disclosed are compounds of Formula A: (structurally represented) where “RG1”, “RG2a”, “RG4”, “RG5”, “MG1”, “n” and “m” are defined herein which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2a receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions. 11. A method of treating a central nervous system disease by administering a compound of .12. A pharmaceutical composition that comprises an inert carrier and a compound of claim 1 , or a pharmaceutically acceptable salt thereof.13. A compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , for use in medicine.14. Use of a compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , for the manufacture of a medicament for the treatment or prevention of a central nervous system disorder.15. A method of treating a central nervous system disorder in a mammalian patient in need thereof by administering a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.16. The method of wherein said central nervous system disorder is a movement disorder associated with Parkinson's disease or the treatment thereof using dopaminergic therapy. The present application claims the benefit of PCT International patent application serial no. PCT/CN2012/087851, filed Dec. 28, 2012, hereby incorporated by reference herein.Adenosine is known to be an endogenous modulator of a number of physiological functions. At the cardiovascular system level, adenosine is a strong vasodilator and a cardiac depressor. On the central nervous system, adenosine induces sedative, anxiolytic and antiepileptic effects. On the respiratory system, adenosine induces bronchoconstriction. At the kidney level, ...

MUTUALLY ASSURED DATA SHARING BETWEEN DISTRUSTING PARTIES IN A NETWORK ENVIRONMENT

An apparatus for sharing information between entities includes a processor and a trusted execution module executing on the processor. The trusted execution module is configured to receive first confidential information from a first client device associated with a first entity, seal the first confidential information within a trusted execution environment, receive second confidential information from a second client device associated with a second entity, seal the second confidential information within the trusted execution environment, and execute code within the trusted execution environment. The code is configured to compute a confidential result based upon the first confidential information and the second confidential information. 1. An apparatus for sharing information between entities , comprising:a processor; and receive first confidential information from a first client device associated with a first entity;', 'seal the first confidential information within a trusted execution environment;', 'receive second confidential information from a second client device associated with a second entity;', 'seal the second confidential information within the trusted execution environment; and', 'execute code within the trusted execution environment, the code configured to compute a confidential result based upon the first confidential information and the second confidential information., 'a trusted execution module executing on the processor, the trusted execution module configured to2. The apparatus of claim 1 , the trusted execution module being further configured to:receive the code from at least one of the first client device and the second client device; andseal the code within the trusted execution environment.3. The apparatus of claim 1 , the trusted execution module being further configured to:determine an identity of the code;send the identity to the first client device; andreceive an indication from the first device that the identity has been verified by the ...

Proactively adjusting network infrastructure in response to reporting of real-time network performance

In one example, the present disclosure describes a device, computer-readable medium, and method for proactively adjusting the infrastructure of a communications network in response to reporting of real-time network performance. For instance, in one example, a method includes obtaining real-time network performance metrics directly from a user endpoint device operated by a customer of a telecommunication service provider network, correlating the real-time network performance metrics with data from another data source, wherein the data includes data other than network performance metrics, and adjusting an infrastructure of the telecommunication service provider network in response to an insight gleaned through the correlating.

HYDROXYALKYLAMINE- and HYDROXYCYCLOALKYLAMINE-SUBSTITUTED DIAMINE-ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS

Disclosed are compounds of Formula A, or a salt thereof: 2) A compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein Ris —Cl or —Br.11) A compound of any of to claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein X is ═N—.12) A compound of any of to claim 1 , or or a pharmaceutically acceptable salt thereof claim 1 , wherein X is ═CH— claim 1 , ═C(CH)— claim 1 , or ═CF—.13) A compound claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , which is:4-[(4-{[(2S)-3-amino-2-hydroxypropyl]amino}butyl)amino]-5-chloro-2-fluoro-N-1,2,4-thiadiazol-5-ylbenzenesulfonamide;4-[(4-{[3-amino-2-hydroxypropyl]amino}butyl)amino]-5-chloro-2-fluoro-N-1,2,4-thiadiazol-5-ylbenzenesulfonamide;4-({4-[3-(aminomethyl)-3-hydroxyazetidin-1-yl]butyl}amino)-5-chloro-2-fluoro-N-(5-fluoro-1,3-thiazol-2-yl)benzenesulfonamide;4-({4-[3-(aminomethyl)-3-hydroxyazetidin-1-yl]butyl}amino)-5-chloro-2-fluoro-N-1,2,4-thiadiazol-5-ylbenzenesulfonamide;2-fluoro-N-(5-fluoro-1,3-thiazol-2-yl)-4-[(4-{[(3-hydroxyazetidin-3-yl)methyl]amino}butyl)amino]-5-methylbenzenesulfonamide;5-bromo-2-fluoro-4-[(4-{[(3-hydroxyazetidin-3-yl)methyl]amino}butyl)amino]-N-1,2,4-thiadiazol-5-ylbenzenesulfonamide;4-[(4-{[(2R)-3-amino-2-hydroxypropyl]-amino}butyl)amino]-5-chloro-2-fluoro-N-1,2,4-thiadiazol-5-yl-benzenesulfonamide;4-[(4-{[(2S)-3-amino-2-hydroxypropyl]-amino}butyl)amino]-5-bromo-2-fluoro-N-1,2,4-thiadiazol-5-yl-benzenesulfonamide;4-[(4-{[(2R)-3-amino-2-hydroxypropyl]-amino}-butyl)amino]-5-bromo-2-fluoro-N-1,2,4-thiadiazol-5-yl-benzenesulfonamide;4-[(4-{[3-amino-2-hydroxypropyl]-amino}-butyl)amino]-5-bromo-2-fluoro-N-1,2,4-thiadiazol-5-yl-benzenesulfonamide;5-chloro-2-fluoro-4-[(4-{[(3-hydroxyazetidin-3-yl)methyl]amino}butyl)amino]-N-(4-methyl-1,3-thiazol-2-yl)-benzenesulfonamide;5-chloro-2-fluoro-4-[(4-{[(3-hydroxyazetidin-3-yl)methyl]amino}butyl)amino]-N-1,2,4-thiadiazol-5-ylbenzenesulfonamide;5-chloro-2-fluoro-4-[(4-{[(3R,4R)-4-hydroxypyrrolidin-3-yl]amino ...

BENZOPIPERAZINE DERIVATIVES AS CETP INHIBITORS

Compounds having the structure of Formula Ia, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and may be useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. 2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein:{'sup': '1', 'sub': 3', '3, 'Ris CFor CH;'}{'sup': 2', '8', '8', '2', '8', '9', '8', '9, 'sub': 1', '3', '1', '3', '2', '1', '3', '3', '3', '3', '3, 'Ris phenyl, naphthyl, a 5-6 membered heteroaromatic ring having 1-2 heteroatoms independently selected from N and —(NR)—, or phenyl to which is fused a 5-6-membered heterocyclic ring having 1-2 heteroatoms independently selected from O, S, and —(NR)—, wherein Ris optionally substituted with 1-2 substituent groups independently selected from C-Calkyl, —NRR, —C(═O)NRR, —C(═O)OC-Calkyl, —S(O)C-Calkyl, Cl, F, —CN, and phenyl, wherein phenyl is optionally substituted with 1-3 substituents independently selected from CF, CH, —OCF, —OCH, and halogen, wherein C1-C3 alkyl in all instances is optionally substituted with one group —OH and optionally 1-5 F; and'}{'sup': 8', '9, 'sub': 1', '2, 'Rand Rare each independently selected from H and C-Calkyl.'}3. The compound of claim 2 , or a pharmaceutically acceptable salt thereof claim 2 , wherein:{'sup': 3', '8', '8', '3', '8', '8, 'sub': 5', '6', '1', '3', '1', '3', '1', '3', '1', '3', '3', '3', '3', '3, 'Ris selected from phenyl, naphthyl, a 6-membered heteroaromatic ring having 1-2 heteroatoms independently selected from N and —(NR)—, thienyl, C-Ccycloalkyl optionally having one double bond, and a 6-membered saturated heterocycle having 1-2 heteroatoms independently selected from O, S, N, and NR, wherein Ris optionally substituted with C-Calkyl, —OC-Calkyl, F, Cl, and a 6-membered saturated heterocycle having 1-2 heteroatoms independently selected from O, S, N, and NR, wherein C-Calkyl and OC-Calkyl are optionally substituted with 1-5 F, and the ...

BTK INHIBITORS

The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or pharmaceutically acceptable salts thereof. Formula I or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds in the treatment of Btk mediated disorders. 2. The compound of claim 1 , wherein Ris halogen.3. The compound of claim 1 , wherein Ris CH.4. The compound of selected from the group consisting of:3-{(3R)-1-[(3-methyloxetan-3-yl)carbonyl]piperidin-3-yl}-1-(4-phenoxyphenyl)-1H-pyrazolo[3,4-c]pyridin-7-amine;1-(4-phenoxyphenyl)-3-[(3R)-1-propanoylpiperidin-3-yl]-1H-pyrazolo[3,4-c]pyridin-7-amine;3-[(3R)-1-(cyclopropylcarbonyl)piperidin-3-yl]-1-(4-phenoxyphenyl)-1H-pyrazolo[3,4-c]pyridin-7-amine;3-{(3R)-1-[(2,2-difluorocyclopropyl)carbonyl]piperidin-3-yl}-1-(4-phenoxyphenyl)-1H-pyrazolo[3,4-c]pyridin-7-amine;1-({(3R)-3-[7-amino-1-(4-phenoxyphenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidin-1-yl}carbonyl)cyclopropanol;3-{(3R)-1-[(3,5-dimethylisoxazol-4-yl)carbonyl]piperidin-3-yl}-1-(4-phenoxyphenyl)-1H-pyrazolo[3,4-c]pyridin-7-amine;3-[(3R)-1-(3-methoxypropanoyl)piperidin-3-yl]-1-(4-phenoxyphenyl)-1H-pyrazolo[3,4-c]pyridin-7-amine;3-{(3R)-1-[(1-methylcyclopropyl)carbonyl]piperidin-3-yl}-1-(4-phenoxyphenyl)-1H-pyrazolo[3,4-c]pyridin-7-amine;3-{(3R)-1-[(3,3-difluorocyclobutyl)carbonyl]piperidin-3-yl}-1-(4-phenoxyphenyl)-1H-pyrazolo[3,4-c]pyridin-7-amine;1-({(3R)-3-[7-amino-1-(4-phenoxyphenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidin-1-yl}carbonyl)cyclopropanecarbonitrile;3-[(3R)-1-(methoxyacetyl)piperidin-3-yl]-1-(4-phenoxyphenyl)-1H-pyrazolo[3,4-c]pyridin-7-amine;3-[(3R)-1-(2-methylpropanoyl)piperidin-3-yl]-1-(4-phenoxyphenyl)-1H-pyrazolo[3,4-c]pyridin-7-amine;3-[(3R)-1-(cyclobutylcarbonyl)piperidin-3-yl]-1-(4-phenoxyphenyl)-1H-pyrazolo[3,4-c]pyridin-7-amine;3-[(3R)-1-acetylpiperidin-3-yl]-1-(4- ...

BTK INHIBITORS

The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts or stereoisomers thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders. 4. The compound of selected from the group consisting of:4-(8-amino-3-(2-oxooctahydro-1H-cyclopropa[a]indolizin-5-yl)imidazo[1,5-a]pyrazin-1-yl)-3-ethoxy-N-(4-(trifluoromethyl)pyridin-2-yl)benzamide;4-(8-amino-3-((6′S,8a′R)-1′,1′-difluoro-3′-oxohexahydro-1′H-spiro[cyclopropane-1,2′-indolizin]-6′-yl)imidazo[1,5-a]pyrazin-1-yl)-3-ethoxy-N-(4-(trifluoromethyl)pyridin-2-yl)benzamide;4-(8-amino-3-((6′R,8a′S)-1′,1′-difluoro-3′-oxohexahydro-1′H-spiro[cyclopropane-1,2′-indolizin]-6′-yl)imidazo[1,5-a]pyrazin-1-yl)-3-ethoxy-N-(4-(trifluoromethyl)pyridin-2-yl)benzamide;4-(8-amino-3-((6′R,8a′S)-3′-oxohexahydro-1′H-spiro[cyclopropane-1,2′-indolizin]-6′-yl)imidazo[1,5-a]pyrazin-1-yl)-3-ethoxy-5-fluoro-N-(4-(trifluoromethyl)pyridin-2-yl)benzamide;4-{8-amino-3-[(6′R,8a′S)-1′,3′-dioxohexahydrospiro[cyclopropane-1,2′-indolizin]-6′-yl)imidazo[1,5-a]pyrazin-1-yl}-3-ethoxy-N-[4-(trifluoromethyl)pyridin-2-yl]benzamide;4-{8-amino-3-[(6′R,8a′S)-1′,3′-dioxohexahydrospiro[cyclopropane-1,2′-indolizin]-6′-yl]imidazo[1,5-a]pyrazin-1-yl}-N-[4-(trifluoromethyl)pyridin-2-yl]benzamide;4-{8-amino-3-[(6′R,8a′S)-1′,3′-dioxohexahydrospiro[cyclopropane-1,2′-indolizin]-6′-yl]imidazo[1,5-a]pyrazin-1-yl}-3-fluoro-N-[4-(trifluoromethyl)pyridin-2-yl]benzamide;4-{8-amino-3-[(6′R,8a′S)-1′,3′-dioxohexahydrospiro[cyclopropane-1,2′-indolizin]-6′-yl]imidazo[1,5-a]pyrazin-1-yl}-N-(4-methylpyridin-2-yl)benzamide;4-{8-amino-3-[(6′R,8a′S)-1′,3′-dioxohexahydrospiro[cyclopropane-1,2′-indolizin]-6′-yl]imidazo[1,5-a]pyrazin-1-yl}-N-(4-cyclopropylpyridin-2-yl)benzamide;4-{8-amino-3-[(1′S,6′R,8a′S)-1′-hydroxy-3′- ...

Btk inhibitors

The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds in the treatment of Btk mediated disorders.

DIAMINO-ALKYLAMINO-Linked ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS

Disclosed are compounds of Formula A, or a salt thereof, where Q, X, R1 and R2 are as defined herein, which compounds have properties for inhibiting Na 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A or their salts, and methods of treating pain (acute, post-operative, neuropathic), or cough or itch disorders using the same. 2) A compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein X is —CH═.3) A compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein X is —C(Cl)═.4) A compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein X is —C(F)═.5) A compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein X is —N═.6) A compound of or a pharmaceutically acceptable salt thereof claim 1 , wherein claim 1 , wherein Q is R—NH-D- claim 1 , wherein Ris —H claim 1 , lower alkyl claim 1 , or lower cycloalkyl and Dis linear- or branched-alkyl claim 1 , or a geminalcycloalkyl moiety of up to 6 carbon atoms.13) A composition comprising at least one compound of claim 13 , or a pharmaceutically acceptable salt thereof claim 13 , and at least one pharmaceutically acceptable excipient.14) A composition of comprising additionally an effective amount of at least one other pharmaceutically active ingredient which is: (i) an opioid agonist or antagonist; (ii) a calcium channel antagonist; (iii) an NMDA receptor agonist or antagonist; (iv) a COX-2 selective inhibitor; (v) an NSAID (non-steroidal anti-inflammatory drug); or (vi) paracetamol (APAP) claim 14 , and a pharmaceutically acceptable carrier.16) A method of treating a pain disorder claim 14 , or cough claim 14 , or acute itch or chronic itch disorder comprising administering to a patient in need thereof a therapeutically effective amount of a composition of .17) The composition of that provides an amount of said compound ...

SUBSTITUTED AMINOQUINAZOLINE COMPOUNDS AS A2A ANTAGONIST

The present invention is directed to compounds of generic formula (I): or pharmaceutically acceptable salts thereof that are believed to be useful as an A-receptor antagonist. The invention is further directed to methods of treating a patient (preferably a human) for diseases or disorders in which the A-receptor is involved. The invention further involves use of the compounds as an A-receptor antagonist and/or inhibitor for the preparation of a medicament for the treatment and/or prevention of diseases associated with inhibiting the receptor, which includes central nervous system disorders such as Parkinson's disease. The invention is also directed to pharmaceutical compositions which include an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, and the use of the compounds and pharmaceutical compositions of the invention in the treatment of such diseases. 122-. (canceled)24. The compound according to or a pharmaceutically acceptable salt thereof claim 23 , wherein Ris —OCalkyl and Ris hydrogen.25. The compound according to or a pharmaceutically acceptable salt thereof claim 23 , wherein Ris Cheterocyclyl claim 23 , said heterocycle group optionally substituted with 1 to 3 groups of R.26. The compound according to or a pharmaceutically acceptable salt thereof claim 25 , wherein Ris Cheterocyclyl selected from the group consisting unsubstituted or substituted piperidinyl claim 25 , morpholinyl claim 25 , tetrahydropyranyl claim 25 , azabicyclooctyl claim 25 , azabicyloheptyl claim 25 , azepanyl claim 25 , azetidinyl claim 25 , pyrrolidinyl claim 25 , and piperidinone.27. The compound according to or a pharmaceutically acceptable salt thereof claim 23 , wherein Ris optionally substituted Ccycloalkyl.28. The compound according to or a pharmaceutically acceptable salt thereof claim 27 , wherein Ris selected from the group of optionally substituted cyclohexyl claim 27 , cyclobutyl claim ...

Factor XIa inhibitors

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more compounds of Formula (I), and methods for using the compounds of Formula (I) for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.

Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels

Disclosed are compounds of Formula A, or a salt thereof: Formula (A) wherein R1, R2, and E are defined herein, which compounds have properties for inhibiting Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A or their salts, and methods of treating pain disorders, cough, and itch using the same.

Mutually assured data sharing between distrusting parties in a network environment

An apparatus for sharing information between entities includes a processor and a trusted execution module executing on the processor. The trusted execution module is configured to receive first confidential information from a first client device associated with a first entity, seal the first confidential information within a trusted execution environment, receive second confidential information from a second client device associated with a second entity, seal the second confidential information within the trusted execution environment, and execute code within the trusted execution environment. The code is configured to compute a confidential result based upon the first confidential information and the second confidential information.

3-(4-heteroarylcyclohexylamino) czclopentanecarboxamides as modulators of chemokine receptors

Indazole and azaindazole btk inhibitors

Btk inhibitors

The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts or stereoisomers thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.

Substituted aminoquinazoline compounds as a2a antagonist

Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels

Disclosed are compounds of Formula A, or a salt thereof, where Q, X, R1 and R2 are as defined herein, which compounds have properties for inhibiting Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A or their salts, and methods of treating pain (acute, post-operative, neuropathic), or cough or itch disorders using the same.

DIAMINE-ARYLSULFONAMIDE COMPOUNDS SUBSTITUTED WITH HYDROXIALKYLAMINE AND HYDROXYCLOALKYLAMINE WITH SELECTIVE ACTIVITY IN VOLTAGE-ACTIVATED SODIUM CHANNELS

Se divulga compuestos de fórmula A, o una sal del mismo: en la que R1, R2 y E se defienen en el presente documento, compuestos que tienen propiedades para inhibir los canales de iones Nav 1.7 encontrados en neuronas periféricas y simpáticas. También se describen formulaciones farmacéuticas que comprenden los compuestos de fórmula A o sus sales, y procedimientos de tratamiento de trastornos de dolor, tos, y picazón usando las mismas.

Piperazinylpiperidine derivatives as chemokine receptor antagonists

The present invention relates to compounds of Formula I: wherein variable substituents are defined herein, that modulate the activity of or bind to chemokine receptors such as CCR5. In some embodiments, the compounds of the invention are selective for CCR5. The compounds can be used, for example, to treat diseases associated with chemokine receptor expression or activity such as inflammatory diseases, immune diseases and viral infections.

Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents

Novel compounds of structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.

DIAMINE-ARILSULFONAMIDE COMPOUNDS REPLACED WITH HYDROXIALYCHILAMINE AND HYDROXYCYCALYLAMINE WITH SELECTIVE ACTIVITY IN VOLTAGE ACTIVATED SODIUM CHANNELS

SE DIVULGAN COMPUESTOS DE FORMULA A O UNA SAL DEL MISMO, (VER FORMULA) EN LA QUE R1, R2 Y E SE DEFINEN EN EL PRESENTE DOCUMENTO, COMPUESTOS QUE TIENEN PROPIEDADES PARA INHIBIR LOS CANALES DE IONES NAV1.7 ENCONTRADOS EN NEURONAS PERIFERICAS Y SIMPATICAS. TAMBIEN SE DESCRIBEN FORMULACIONES FARMACEUTICAS QUE CONPRENDEN LOS COMPUESTOS DE FORMULA A O SUS SALES, Y PROCEDIMIENTOS DE TRATAMIENTO DE TRASTORNOS DE DOLOR, TOS Y PICAZON USANDO LAS MISMAS

BTK Inhibitors

Provided are 6-5 membered fused pyridine ring compounds according to Formula (I) or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and their use in therapy. In particular, provided is the use of 6-5 membered fused pyridine ring compounds in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.

3-(4-Heteroarylcyclohexylamino)cyclopentanecarboxamides as modulators of chemokine receptors

The present invention is directed to compounds of Formula I: which are modulators of chemokine receptors. The compounds of the invention, and compositions thereof, are useful in the treatment of diseases related to chemokine receptor expression and/or activity.

DIAMINE-ARYLSULFONAMIDE COMPOUNDS SUBSTITUTED WITH HYDROXIALKYLAMINE AND HYDROXYCLOALKYLAMINE WITH SELECTIVE ACTIVITY IN VOLTAGE-ACTIVATED SODIUM CHANNELS

Se divulgan compuestos de fórmula A, o una sal del mismo (la fórmula se describe por la imagen adjunta) en la que R1, R2 y E se definen en el presente documento, compuestos que tienen propiedades para inhibir los canales de iones Nav1.7 encontrados en neuronas periféricas y simpáticas. También se describen formulaciones farmacéuticas que comprenden los compuestos de fórmula A o sus sales, y procedimientos de tratamiento de trastornos de dolor, tos, y picazón usando las mismas.

Benzopiperazine derivatives as cetp inhibitors

Compounds having the structure of Formula Ia, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and may be useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis.

Secure key derivation and cryptography logic for integrated circuits

A processor of an aspect includes root key generation logic to generate a root key. The root key generation logic includes a source of static and entropic bits. The processor also includes key derivation logic coupled with the root key generation logic. The key derivation logic is to derive one or more keys from the root key. The processor also includes cryptographic primitive logic coupled with the root key generation logic. The cryptographic primitive logic is to perform cryptographic operations. The processor also includes a security boundary containing the root key generation logic, the key derivation logic, and the cryptographic primitive logic. Other processors, methods, and systems are also disclosed.

Methods, systems and apparatus to facilitate client-based authentication

Btk inhibitors

The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or pharmaceutically acceptable salts thereof Formula I or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds in the treatment of Btk mediated disorders.

Piperazinylpiperidine derivatives as chemokine receptor antagonists

Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels

Disclosed are compounds of Formula A, or a salt thereof, where Q, X, R1 and R2 are as defined herein, which compounds have properties for inhibiting Na v 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A or their salts, and methods of treating pain (acute, post-operative, neuropathic), or cough or itch disorders using the same.

DIAMINE-ARYLSULFONAMIDE COMPOUNDS SUBSTITUTED WITH HYDROXIALKYLAMINE AND HYDROXYCLOALKYLAMINE WITH SELECTIVE ACTIVITY IN VOLTAGE-ACTIVATED SODIUM CHANNELS

Referido a compuestos de formula A, o una sal de este, en la que R1 es -Cl, Br, o alquilo lineal, ramificado o ciclico de hasta 3 atomos de carbono; R2 es un resto de la formula (a), en la que uno de R3a y R3b es -H y el otro es -H, F, CH3; o un resto de la formula (b); E es un resto de la formula E1, en la que R6 es H o un alquilo lineal, ramificado o ciclico de hasta 6 atomos de carbono; y B es un resto de la formula (c), en donde se une a nitrogeno en uno de R7A, R7B, o R7C por medio de -CH2- , o se une a nitrogeno directamente en uno de R7C; m es 0, 1 o 2; R7D es -H, alquilo lineal, ramificado, o ciclico de hasta 5 atomos de carbono, entre otros. Estos compuestos de diamina-arilsulfonamida sustituidos con hidroxialquilamina e hidroxicicloalquilamina tienen propiedades para inhibir los canales de iones Na v 1.7 encontrados en neuronas perifericas y simpaticas. Tambien se refiere a formulaciones farmaceuticas que comprenden los compuestos de formula A o sus sales, y procedimientos de tratamiento de trastornos de dolor, tos, y picazon usando las mismas. Relating to compounds of formula A, or a salt thereof, wherein R1 is -Cl, Br, or linear, branched or cyclic alkyl of up to 3 carbon atoms; R2 is a residue of formula (a), wherein one of R3a and R3b is -H and the other is -H, F, CH3; or a remainder of formula (b); E is a residue of formula E1, where R6 is H or a linear, branched or cyclic alkyl of up to 6 carbon atoms; and B is a moiety of formula (c), wherein it binds nitrogen at one of R7A, R7B, or R7C via -CH2-, or binds nitrogen directly at one of R7C; m is 0, 1 or 2; R7D is -H, linear, branched, or cyclic alkyl of up to 5 carbon atoms, among others. These hydroxyalkylamine and hydroxycycloalkylamine substituted diamine-arylsulfonamide compounds have properties to inhibit Na v 1.7 ion channels found in peripheral and sympathetic neurons. It also relates to pharmaceutical formulations comprising the compounds of formula A or their salts, and methods of treating ...

Benzopiperazine derivatives as cetp inhibitors

3-(4-heteroarylcyclohexylamino) cyclopentanecarboxamides as modulators of chemokine receptors

Btk inhibitors

Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels

Piperazinylpiperidine derivatives as chemokine receptor antagonists

Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels

Disclosed are compounds of Formula A, or a salt thereof: Formula (A), wherein: Het, Q and R1A to R4A are defined herein, which compounds have properties for blocking Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A or their salts, and methods of treating cough, itch, acute pain and neuropathic pain disorders using the same.

Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels

Secured credential aggregator

An apparatus for aggregating secured credentials is described herein. The apparatus includes a processor and a memory. The memory includes code causing the processor to provision a plurality of secured credentials on the apparatus. The code causes the processor to isolate the secured credentials from each other in the memory. The code also causes the processor to emulate a selected secured credential from the secured credentials for a transaction.

Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment

Substituted cyclopropyl compounds of the formula I: and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR-119. Pharmaceutical compositions and methods of treatment are also included

Secured credential aggregator

Proactively adjusting network infrastructure in response to reporting of real-time network performance

In one example, the present disclosure describes a device, computer-readable medium, and method for proactively adjusting the infrastructure of a communications network in response to reporting of real-time network performance. For instance, in one example, a method includes obtaining real-time network performance metrics directly from a user endpoint device operated by a customer of a telecommunication service provider network, correlating the real-time network performance metrics with data from another data source, wherein the data includes data other than network performance metrics, and adjusting an infrastructure of the telecommunication service provider network in response to an insight gleaned through the correlating.

Integrated circuits having accessible and inaccessible physically unclonable functions

An integrated circuit substrate of an aspect includes a plurality of exposed electrical contacts. The integrated circuit substrate also includes an inaccessible set of Physically Unclonable Function (PUF) cells to generate an inaccessible set of PUF bits that are not accessible through the exposed electrical contacts. The integrated circuit substrate also includes an accessible set of PUF cells to generate an accessible set of PUF bits that are accessible through the exposed electrical contacts. Other apparatus, methods, and systems are also disclosed.

Secured credential aggregator

An apparatus for aggregating secured credentials is described herein. The apparatus includes a processor and a memory. The memory includes code causing the processor to provision a plurality of secured credentials on the apparatus. The code causes the processor to isolate the secured credentials from each other in the memory. The code also causes the processor to emulate a selected secured credential from the secured credentials for a transaction.

Techniques for shared private data objects in a trusted execution environment

Techniques for sharing private data objects in a trusted execution environment using a distributed ledger are described. The techniques described herein may enable sharing of data objects, referred to herein as private data objects (PDOs), between individuals and organizations with access and update policies mediated by execution of code (referred to herein as a “smart contract”) carried with the PDO in a secure enclave. A distributed ledger may serve as a “public commit log” to ensure that there is a single, authoritative instance of the object and provide a means of guaranteeing atomicity of updates across interacting objects.

Cyclohexylgycine derivatives as selective cytotoxic agents

The present disclosure is directed to cyclohexylglycine derivatives of Formula Iand their use as HIV-infected cell kill agents which accelerate the death of HIV GAG-POL expressing cells without concomitant cytotoxicity to HIV naïve cells.

Proactively adjusting network infrastructure in response to reporting of real-time network performance

In one example, the present disclosure describes a device, computer-readable medium, and method for proactively adjusting the infrastructure of a communications network in response to reporting of real-time network performance. For instance, in one example, a method includes obtaining real-time network performance metrics directly from a user endpoint device operated by a customer of a telecommunication service provider network, correlating the real-time network performance metrics with data from another data source, wherein the data includes data other than network performance metrics, and adjusting an infrastructure of the telecommunication service provider network in response to an insight gleaned through the correlating.

Automated secure check-out and drop-off return of products using mobile device

Generally, this disclosure describes a method and system for automated check-out and drop-off return of products using a mobile device. A method may include purchasing at least one product of a plurality of products wherein each product is located at a respective associated product location in a store that sells the plurality of products and a point of sale of each purchased product corresponds to the respective associated product location.

System and method for preparing hydrocarbon blend from multiple component streams

A computer implemented blend control system and method for preparation of a hydrocarbon blend from a plurality of components drawn from respective component tanks have been disclosed. The system, in accordance with the present disclosure includes at least one sensor and analyzer adapted to sense and analyze a first attribute of at least one of the components for obtaining first attribute data. The system further includes, at least one optimizer having a data storage means for storing attribute based model data. The optimizer receives the first attribute data and transmits the received first attribute data to a comparator which computes an optimized proportion data between each of the component streams to enable selective drawing of each of the component streams in accordance with the optimized proportion data for preparing the hydrocarbon blend.

Computer implemented blend control system and method for preparation of a hydrocarbon blend

A computer implemented blend control system and method for preparation of a hydrocarbon blend from a plurality of component streams have been disclosed. The system includes a product tank for receiving a mixture comprising the plurality of component streams. The system further includes a sensor and analyzer adapted to sense and analyze a first attribute of the received mixture for obtaining a first attribute data. The system further includes an optimizer which stores the attribute based model data, receives the first attribute data and compares the received first attribute data with the attribute based model data to compute an optimized proportion data, based on which the component streams are selectively drawn into the product tank for preparing the hydrocarbon blend.